Richard Szydlo

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marín, Alexandra Bazeos, François-Xavier Mahon et al. · Journal of Clinical Oncology · 2010 · 901 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad et al. · Journal of Clinical Oncology · 2008 · 556 citations

Medicine, Hematology, Pharmacology +8

Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.

Richard Szydlo, John M. Goldman, John P. Klein et al. · Journal of Clinical Oncology · 1997 · 475 citations

Life Sciences, Hematology, Immunology +17

Assessment of <i>BCR-ABL1</i> Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

David Marín, Amr R. Ibrahim, Claire Lucas et al. · Journal of Clinical Oncology · 2011 · 475 citations

Medicine, Hematology, Oncology +13

Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC

Tom Vulliamy, Anna Marrone, Richard Szydlo et al. · Nature Genetics · 2004 · 463 citations

Life Sciences, Genetics, Molecular Genetics +14